USFDA pulls up Aurobindo Pharma for manufacturing lapses at API plant


USFDA pulls up Aurobindo Pharma for manufacturing lapses at API plant In a letter to company’s Managing Director Narayanan Govindarajan, the US health regulator noted that its inspectors during an inspection between August 2-12, 2021, found significant deviations from standard manufacturing practices for active pharmaceutical ingredients (API) at the company’s Doultabad-based plant.